Pancreatic Cancer Research

ResearcherNational Cancer Centre JapanActive in the last 2 years

Yusuke Sano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7753-8712; OpenAlex author ID A5125511072. Sources: OpenAlex.

Their work

Papers
6
Trials
0
Grants
0
Labs led
0
Collaborators
59
Papers, trials and grants by year

2024: 2 papers · 2025: 2 papers · 2026: 2 papers

Papers 6

  1. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  2. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  3. Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: A supplementary analysis of JCOG1407. Co-author DOI 10.1016/j.pan.2025.02.005↗
  4. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  5. Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline re… Co-author DOI 10.1093/jjco/hyae084↗
  6. A multi-institutional randomized phase III study comparing minimally invasive distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer; Ja… Co-author DOI 10.1186/s12885-024-11957-9↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Makoto Ueno · 5 shared papers, 2024–2026 · strength 0.95
  2. Masato Ozaka · 4 shared papers, 2024–2026 · strength 0.80
  3. Masashi Kanai · 3 shared papers, 2024–2026 · strength 0.60
  4. Junji Furuse · 3 shared papers, 2024–2026 · strength 0.60
  5. Satoshi Kobayashi · 2 shared papers, 2025–2026 · strength 0.40
  6. Masafumi Ikeda · 2 shared papers, 2025–2026 · strength 0.40
  7. Yukiko Takayama · 2 shared papers, 2025–2026 · strength 0.40
  8. Nao Fujimori · 2 shared papers, 2025–2026 · strength 0.40
  9. Junki Mizusawa · 2 shared papers, 2024–2026 · strength 0.35
  10. Amane Takahashi · 2 shared papers, 2024–2026 · strength 0.35
  11. Shintaro Yagi · 2 shared papers, 2024–2026 · strength 0.35
  12. Keiko Kamei · 2 shared papers, 2024–2026 · strength 0.35
  13. Naoto Gotohda · 2 shared papers, 2024–2026 · strength 0.35
  14. Seiko Hirono · 2 shared papers, 2024–2026 · strength 0.35
  15. Etsuro Hatano · 2 shared papers, 2024–2026 · strength 0.35
  16. Naoki Ikenaga · 2 shared papers, 2024–2026 · strength 0.35
  17. Michiaki Unno · 2 shared papers, 2024–2026 · strength 0.35
  18. Michio Yoshimura · 1 shared paper, 2024 · strength 0.21
  19. Chigusa Morizane · 1 shared paper, 2024 · strength 0.21
  20. Satoaki Nakamura · 1 shared paper, 2026 · strength 0.20
  21. Kentaro Yamazaki · 1 shared paper, 2026 · strength 0.20
  22. Tatsuya Ioka · 1 shared paper, 2026 · strength 0.20
  23. Yoshito Komatsu · 1 shared paper, 2026 · strength 0.20
  24. Taro Yamashita · 1 shared paper, 2026 · strength 0.20
  25. Kazuo Hara · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.